# Fujirebio

Source: https://onco.cc/companies/fujirebio/  
OnCo record `fujirebio` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The Japanese immunoassay company, part of H.U. Group, whose Malvern, Pennsylvania laboratory holds the original CA 19-9 and CA-125 tumour marker assays and licenses the antibodies to the big analyser makers.

## Summary

Fujirebio is a Tokyo-based in vitro diagnostics company within H.U. Group Holdings. Its United States subsidiary, Fujirebio Diagnostics in Malvern, Pennsylvania, descends from Centocor Diagnostics, where the CA 19-9 and CA-125 immunoassays were developed in the early 1980s, and it still supplies the reference antibodies and assays (CA 19-9, CA-125 II, HE4, CYFRA 21-1, ProGRP) that run on its own Lumipulse analysers and, under licence, on the platforms of other manufacturers. The company is also a major supplier of Alzheimer's disease biomarker tests, and its oncology business centres on ovarian, pancreatic and lung cancer markers.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Fujirebio Diagnostics; H.U. Group
- HQ: Tokyo, Japan
- Type: diagnostics
- Website: https://www.fujirebio.com

## Sources

- Official website: https://www.fujirebio.com

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- technologies: [Proteomics instruments and affinity platforms](https://onco.cc/technologies/proteomics-platforms/), [Serum tumour markers: proper use and misuse](https://onco.cc/technologies/serum-tumour-markers/)

---
JSON: https://onco.cc/api/v1/entities/fujirebio.json